S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:ACRX

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

$0.27
-0.04 (-12.90%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.26
$0.28
50-Day Range
$0.18
$0.35
52-Week Range
$0.16
$1.20
Volume
5.69 million shs
Average Volume
3.49 million shs
Market Capitalization
$39.72 million
P/E Ratio
0.93
Dividend Yield
N/A
Price Target
$5.00

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,751.9% Upside
$5.00 Price Target
Short Interest
Bearish
8.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.81mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$10,208 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.23) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

257th out of 1,135 stocks

Pharmaceutical Preparations Industry

119th out of 557 stocks

ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

AcelRx Pharmaceuticals Stock Down 13.6 %

Shares of AcelRx Pharmaceuticals stock traded down $0.04 on Friday, hitting $0.27. 5,687,353 shares of the company were exchanged, compared to its average volume of 3,490,330. The company has a 50-day moving average price of $0.23 and a 200 day moving average price of $0.29. The stock has a market capitalization of $39.72 million, a price-to-earnings ratio of 0.93 and a beta of 0.44. AcelRx Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.20.

AcelRx Pharmaceuticals (NASDAQ:ACRX - Get Rating) last issued its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06). During the same period last year, the company earned ($0.08) earnings per share. Research analysts forecast that AcelRx Pharmaceuticals will post -0.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals in a report on Tuesday. They set a "sell" rating for the company.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

AcelRx Pharmaceuticals (ACRX) to Release Earnings on Thursday
Why AcelRx Pharma Shares Are Trading Higher Today?
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings
8/11/2022
Today
8/14/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,751.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-35,100,000.00
Net Margins
1,588.91%
Pretax Margin
-1,266.35%

Debt

Sales & Book Value

Annual Sales
$2.82 million
Book Value
($0.30) per share

Miscellaneous

Free Float
139,023,000
Market Cap
$39.72 million
Optionable
Optionable
Beta
0.44

Key Executives

  • Mr. Vincent J. Angotti (Age 54)
    CEO & Director
    Comp: $915.29k
  • Dr. Pamela Pierce Palmer M.D. (Age 59)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $682k
  • Mr. Raffi Mark Asadorian (Age 53)
    Chief Financial Officer
    Comp: $623.1k
  • Mr. Lawrence G. Hamel (Age 70)
    Consultant
  • Mr. Anil N. Dasu (Age 59)
    Chief Engineering Officer













ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings
or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price forecast for 2022?

2 brokerages have issued 1 year price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price forecasts range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,751.9% from the stock's current price.
View analysts price targets for ACRX
or view top-rated stocks among Wall Street analysts.

How have ACRX shares performed in 2022?

AcelRx Pharmaceuticals' stock was trading at $0.56 at the beginning of 2022. Since then, ACRX shares have decreased by 51.8% and is now trading at $0.27.
View the best growth stocks for 2022 here
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Thursday, August, 11th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). During the same quarter in the prior year, the company posted ($0.08) EPS.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Values First Advisors Inc. (0.52%), Virtu Financial LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.27.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $39.72 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $0.29 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.